

BMY Suspended dosing of Inhibitex HCV drug - Valuations stretched and there is no room for negative news

https://marketpublishers.com/r/B74B39ACE9DEN.html

Date: August 2012

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: B74B39ACE9DEN

Abstracts

Voluntary suspension of dosing of BMS-986094 in an ongoing PhII study due to the serious safety issue (cardiac failure) observed in high dose arm (200 mg) is clearly negative and we see the potential risk-reward profile of an investment in BMY at the current valuations unfavorable. With the kind of competitive dynamics in HCV pipeline, we see BMY strength in this space as very much diluted.



Contents

COMPANIES MENTIONED

Bristole -Myers Squibb



I would like to order

Product name: BMY Suspended dosing of Inhibitex HCV drug - Valuations stretched and there is no

room for negative news

Product link: https://marketpublishers.com/r/B74B39ACE9DEN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/B74B39ACE9DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



